CRIS / Curis, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 21, 2025 Curis, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 21, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

Calculation of Filing Fee Tables Form S-1 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule A

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa

As filed with the Securities and Exchange Commission on August 8, 2025

As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 8, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Up to $8,137,047 COMMON STOCK

Filed pursuant to Rule 424(b)(5) Registration No. 333-276950 PROSPECTUS SUPPLEMENT (to Prospectus dated April 12, 2024) Up to $8,137,047 COMMON STOCK We previously entered into an Amended and Restated Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor, and JonesTrading Institutional Services LLC, or Jones, dated February 8, 2024, relating to shares of our common stock, $0

Curis Provides Second Quarter 2025 Business Update Management to host conference call and webcast today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2025 Business Update Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., August 5, 2025 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating resu

Employment Agreement, dated May 1, 2025, by and between Curis, Inc. and Ahmed Hamdy

EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), is entered into by and between Curis, Inc., a Delaware corporation (the “Company”), and Ahmed Hamdy, M.D. (the “Employee”). WHEREAS the Company desires to employ the Employee, and the Employee desires to be employed by the Company on the terms set forth in this Agreement. In consideration of the mutual covenants and pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2025 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

1,538,460 Shares COMMON STOCK

Filed pursuant to Rule 424(b)(5) Registration No. 333-276950 PROSPECTUS SUPPLEMENT (to Prospectus dated April 12, 2024) 1,538,460 Shares COMMON STOCK We are offering 1,538,460 shares of our common stock to investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with each investor. In a concurrent private placement, or the Warrant Private

CURIS, INC.

Issuer Free Writing Prospectus dated July 2, 2025 Filed Pursuant to Rule 433 Registration No.

Registration Rights Agreement, dated July 2, 2025, by and among the Company and the Purchasers named therein

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 2, 2025, by and among Curis, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purchase Agreement”). Capitalized terms us

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 1, 2025 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 1, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

Form of Unregistered Pre-Funded Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

Exhibit 99.2 PRESS RELEASE Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement LEXINGTON, Mass., July 2, 2025 /PRNewswire/ - Curis, Inc. (“Curis”) (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combinat

Securities Purchase Agreement, dated July 2, 2025, by and among the Company and the Purchasers named therein

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 2, 2025, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in

Form of Unregistered Common Warrant

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Corporate Presentation July 2025 Exhibit 99.1 2 This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Wor

a2025-07corporatepresent Corporate Presentation July 2025 Exhibit 99.1 2 This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,” “may,” “anticipate(s),” “focus(es),” “plans,” “mission,” “strategy,” “potential

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 20, 2025 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 20, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

Amended and Restated By-laws of Curis, Inc.

Exhibit 3.2 CURIS, INC. AMENDED AND RESTATED BY-LAWS (Amended and Restated as of May 20, 2025) TABLE OF CONTENTS Section 1. Certificate of Incorporation and By-Laws 1 1.1. Conflicts 1 1.2. References 1 Section 2. Offices 1 2.1. Registered Office 1 2.2. Other Offices 1 Section 3. Stockholders 1 3.1. Location of Meetings 1 3.2. Annual Meeting 1 3.3. Special Meeting in Place of Annual Meeting 1 3.4.

Restated Certificate of Incorporation of Curis, Inc., as amended

EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. CURIS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of St

128 Spring Street | Building C – Suite 500 | Lexington, MA 02421-3112 | www.curis.com | Phone 617.503.6500

May 15, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Tyler Howes Re: Curis, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa

As filed with the Securities and Exchange Commission on May 6, 2025

As filed with the Securities and Exchange Commission on May 6, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2025 Curis, Inc. (Exact Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S

Curis Provides First Quarter 2025 Business Update Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides First Quarter 2025 Business Update Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 6, 2025 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Terms and Conditions of Nonstatutory Stock Option Agreement

Exhibit 10.28 Terms and Conditions of Nonstatutory Stock Option Agreement 1.Grant of Option. This agreement evidences the grant by Curis, Inc., a Delaware corporation (the “Company”), on the Grant Date to the Participant, [an employee][a director] of the Company, of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s Fifth Amended and Restated 2010 Stock I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

CURIS, INC.

Issuer Free Writing Prospectus dated March 28, 2025 Filed Pursuant to Rule 433 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specifie

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Curis, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our by-laws and applicable provision

Third Amended and Restated Insider Trading Policy

EX-19 6 curis-thirdrestatedinsider.htm EX-19 EXHIBIT 19 Third Amended and Restated Insider Trading Policy Date: December 2023 Page 1 of 9 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “Exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2025 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

SUBSIDIARIES OF THE REGISTRANT

EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

Terms and Conditions of Incentive Stock Option Agreement

Exhibit 10.27 Terms and Conditions of Incentive Stock Option Agreement 1.Grant of Option. This agreement evidences the grant by Curis, Inc., a Delaware corporation (the “Company”), on the Grant Date to the Participant, an employee of the Company, of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s Fifth Amended and Restated 2010 Stock Incentive Plan (th

Dodd-Frank Compensation Recovery Policy

EXHIBIT 97 Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Curis, Inc.

By clicking “Accept”, you and the Company agree that these options are granted under and governed by the terms and conditions of the Company's Stock Option Plan as amended and the Option Agreement all of which are attached and made a part of this doc

EXHIBIT 10.23 Notice of Grant of Stock Options and Option Agreement Curis, Inc. ID: 04-3505116 128 Spring Street Lexington, MA 02421 %%FIRSTNAME%-% %%LASTNAME%-% Option Number: %%OPTIONNUMBER%-% %%ADDRESSLINE1%-% Plan: %%EQUITYPLAN%-% %%CITY%-%, %%STATE%-% %%ZIPCODE%-% ID: %%EMPLOYEEIDENTIFIER%-% Effective %%OPTIONDATE,'MM/DD/YYYY'%-% (“Grant Date”), you have been granted a(n) Non-Qualified Stock

Curis Provides Fourth Quarter 2024 Business Update FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call tod

Exhibit 99.1 PRESS RELEASE Curis Provides Fourth Quarter 2024 Business Update FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., March 31, 2025 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focu

1,974,432 Shares COMMON STOCK

Filed pursuant to Rule 424(b)(5) Registration No. 333-276950 PROSPECTUS SUPPLEMENT (to Prospectus dated April 12, 2024) 1,974,432 Shares COMMON STOCK We are offering 1,974,432 shares of our common stock to investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with each investor. In a concurrent private placement, or the Warrant Private

(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on March 28, 2025)

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2025, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i

Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on March 28, 2025)

EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 28, 2025)

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

(incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on March 28, 2025

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 28, 2025, by and among Curis, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purchase Agreement”). Capitalized terms

UNAUDITED FINANCIAL INFORMATION CURIS, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share data) December 31, 2024 2023 ASSETS Cash, cash equivalents and investments $ 19,997 $ 56,334 Restri

EXHIBIT 99.1 UNAUDITED FINANCIAL INFORMATION CURIS, INC. AND SUBSIDIARIES Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share data) December 31, 2024 2023 ASSETS Cash, cash equivalents and investments $ 19,997 $ 56,334 Restricted cash 544 544 Accounts receivable 3,349 2,794 Prepaid expenses and other assets 4,999 5,138 Property and equipment, net 231 434 Opera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 28, 2025 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 28, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 21, 2025 Curis, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 21, 2025 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number)

January 3, 2025

January 3, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jessica Dickerson Re: Curis, Inc.

As filed with the Securities and Exchange Commission on December 23, 2024

As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Fourth Amendment to Collaboration, License and Option Agreement, dated September 16, 2024, by and between Curis, Inc. and Aurigene Discovery Technologies Limite

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FOURTH AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT This Fourth Amendment to Collaboration, License and Option Agreement (this “Fourth Amendment”)

Third Amendment to Collaboration, License and Option Agreement, dated June 4, 2020, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. THIRD AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT This Third Amendment to Collaboration, License and Option Agreement (this “Third Amendment”) is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

Curis Provides Third Quarter 2024 Business Update Management to host conference call today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2024 Business Update Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ - Curis, Inc. (“Curis”) (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial re

CRIS / Curis, Inc. / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment

SC 13G/A 1 d1152836413g-a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

CRIS / Curis, Inc. / SATTERFIELD THOMAS A JR - SCHEDULE 13G Passive Investment

SC 13G 1 tm2427347d1sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Curis, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269309 (CUSIP Number) October 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Securities Purchase Agreement, dated October 28, 2024, by and among the Company and the Purchasers named therein

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 28, 2024, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth

2,398,414 Shares COMMON STOCK

Filed pursuant to Rule 424(b)(5) Registration No. 333-276950 PROSPECTUS SUPPLEMENT (to Prospectus dated April 12, 2024) 2,398,414 Shares COMMON STOCK We are offering 2,398,414 shares of our common stock to investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with each investor. In a concurrent private placement, or the Warrant Private

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 28, 2024 Curis, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 28, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Exhibit 99.1 PRESS RELEASE Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ ─ Curis, Inc. (“Curis”) (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combin

Form of Unregistered Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Registration Rights Agreement, dated October 28, 2024, by and among the Company and the Purchasers named therein

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of October 28, 2024, by and among Curis, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purchase Agreement”). Capitalized term

CURIS, INC.

Issuer Free Writing Prospectus dated October 28, 2024 Filed Pursuant to Rule 433 Registration No.

Curis Provides Second Quarter 2024 Financial and Operating Update EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2024 Financial and Operating Update EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., August 1, 2024 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 1, 2024 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 1, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per sh

As filed with the Securities and Exchange Commission on June 14, 2024

As filed with the Securities and Exchange Commission on June 14, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 21, 2024 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 21, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

(incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed May 23, 2024

EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. CURIS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of St

CURIS, INC. AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN

Exhibit 99.2 CURIS, INC. AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2010 Employee Stock Purchase Plan of Curis, Inc. 1. Purpose. The purpose of the Plan is to provide eligible employees of the Company and its Designated Subsidiaries with opportunities to purchase shares of Common Stock through accumulated payroll deduc

CURIS, INC. FIFTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN

Exhibit 99.1 CURIS, INC. FIFTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Fifth Amended and Restated 2010 Stock Incentive Plan (the “Plan”) of Curis, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important c

Curis Announces Additional Data from TakeAim Leukemia Study Data update expands AML dataset from 5 to 30 patients

Exhibit 99.1 PRESS RELEASE Curis Announces Additional Data from TakeAim Leukemia Study Data update expands AML dataset from 5 to 30 patients LEXINGTON, Mass., May 14, 2024 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim L

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 14, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

Corporate Presentation May 2024 2 This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “ex

Corporate Presentation May 2024 2 This presentation contains certain forward-looking statements about Curis, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2024 Curis, Inc. (Exact Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 7, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S

Curis Provides First Quarter 2024 Business Update Management to host conference call today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides First Quarter 2024 Business Update Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 7, 2024 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

CRIS / Curis, Inc. / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

April 10, 2024

April 10, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara Re: Curis, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

JOINT FILING AGREEMENT

EX-99.A 2 d788237dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Curis, Inc. dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provi

CRIS / Curis, Inc. / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment

SC 13G/A 1 d788237dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr

Power of Attorney

EX-99.B 3 d788237dex99b.htm EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Trevor Wiessmann as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or a

CRIS / Curis, Inc. / M28 Capital Management LP - CURIS, INC. Passive Investment

SC 13G 1 p24-0363sc13g.htm CURIS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Curis, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 231269309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

As filed with the Securities and Exchange Commission on February 8, 2024

As filed with the Securities and Exchange Commission on February 8, 2024 Registration No.

SUBSIDIARIES OF THE REGISTRANT

EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specifie

AMENDMENT NO. 1 SALES AGREEMENT

Exhibit 10.45 AMENDMENT NO. 1 TO SALES AGREEMENT August 12, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies and Gentlemen: Curis, Inc. (the “Company”), Cantor Fitzgerald & Co. (“Cantor”) and JonesTrading Institutional Services LLC (“JonesTrading”, each of Cantor and JonesTrading indiv

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa

Curis Provides Fourth Quarter 2023 Business Update Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call tod

Exhibit 99.1 PRESS RELEASE Curis Provides Fourth Quarter 2023 Business Update Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., February 8, 2024 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company fo

Dodd-Frank Compensation Recovery Policy

EXHIBIT 97 Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Curis, Inc.

As filed with the Securities and Exchange Commission on February 8, 2024

As filed with the Securities and Exchange Commission on February 8, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 8, 2024 Curis, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 8, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per sh

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

EXHIBIT 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), made as of November 1, 2023 (the “Effective Date”), is entered into by and between Curis, Inc., a Delaware corporation (the “Company”), and Jonathan B. Zung (the “Employee”). WHEREAS, the Company and the Employee are parties to an Employment Agreement dated as of May 1, 2023 (th

Amended and Restated Sales Agreement by and among Curis, Inc., Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC dated February 8, 202

Exhibit 1.2 CURIS, INC. Common Stock ($0.01 par value per share) Amended and Restated Sales Agreement February 8, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, NY 10013 Ladies and Gentlemen: Curis, Inc., a Delaware corporation (the “Company”) and Cantor Fitzgerald & Co. (“Cantor”) and JonesTrading

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Curis, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our by-laws and applicable provision

Corporate Presentation January 2024 Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private

a2024-01corporatepresent Corporate Presentation January 2024 Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 11, 2024 Curis, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 11, 2024 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

December 21, 2023

December 21, 2023 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Re

Curis Provides Third Quarter 2023 Business Update Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET

Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2023 Business Update Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., November 2, 2023 /PRNewswire/ - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the developme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 2, 2023 Curis, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 2, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 23, 2024)

EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. CURIS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of St

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 26, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Certificate of Amendment of Restated Certificate of Incorporation of Curis, Inc. – Reverse Stock Split

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. Curis, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 26, 2023 Curis, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 26, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Certificate of Amendment of Restated Certificate of Incorporation of Curis, Inc. – Increase In Authorized Shares

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. Curis, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated C

Certificate of Amendment of Restated Certificate of Incorporation of Curis, Inc. – Reverse Stock Split

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. Curis, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated C

Certificate of Amendment of Restated Certificate of Incorporation of Curis, Inc. – Increase In Authorized Shares

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. Curis, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 3, 2023 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 3, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Curis Provides Second Quarter 2023 Business Update Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance she

Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2023 Business Update Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance sheet with $77.4 million in cash and investments; cash runway into 2025 Management to host conference call today at 4:30 p.m.

Employment Agreement, entered into on May 1, 2023, by and between Curis, Inc. and Jonathan Zung

EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), is entered into by and between Curis, Inc., a Delaware corporation (the “Company”), and Jonathan B. Zung (the “Employee”). WHEREAS the Company desires to employ the Employee, and the Employee desires to be employed by the Company on the terms set forth in this Agreement. In consideration of the mutual covenants and prom

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

EXHIBIT 99.1 PRESS RELEASE FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID LEXINGTON, Mass., July 6, 2023 /PRNewswire/ - Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 5, 2023 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 5, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

18,409,756 Shares COMMON STOCK

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254362 PROSPECTUS SUPPLEMENT (to Prospectus dated April 14, 2022) 18,409,756 Shares COMMON STOCK We are offering 18,409,756 shares of our common stock to certain investors pursuant to this prospectus supplement and the accompanying prospectus at an offering price of $0.82 per share. Our common stock is listed on The Nasd

Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc. EXHIBIT 99.2 Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) wi

corporate202307 Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc. EXHIBIT 99.2 Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”

, 2023, by and among Curis, Inc. and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on July

curis-june2023rdoxsecuri EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 5, 2023, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and

Curis Announces $15.1 Million Registered Direct Offering

EXHIBIT 99.1 Curis Announces $15.1 Million Registered Direct Offering LEXINGTON, Mass., July 6, 2023 (PRNEWSWIRE) – Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announced that it has entered into definitive agreements led by existing investors for t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 6, 2023 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 6, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 23, 2023 Curis, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 23, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 4, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S

Curis Provides First Quarter 2023 Business Update Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Developmen

PRESS RELEASE Curis Provides First Quarter 2023 Business Update Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.

Employment Agreement, entered into on May 1, 2023, by and between Curis, Inc. and Jonathan Zung

EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), is entered into by and between Curis, Inc., a Delaware corporation (the “Company”), and Jonathan B. Zung (the “Employee”). WHEREAS the Company desires to employ the Employee, and the Employee desires to be employed by the Company on the terms set forth in this Agreement. In consideration of the mutual covenants and prom

Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 20, 2023 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 20, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Com

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specifie

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 14 CURIS, INC. AMENDED AND RESTATED CODE OF BUSINESS CONDUCT AND ETHICS Adopted: December 12, 2017 This Code of Business Conduct and Ethics (the “Code”) sets forth legal and ethical standards of conduct for directors, officers and employees of Curis, Inc. (the “Company”). This Code is intended to deter wrongdoing and to promote the conduct of all Company business in accordance with high st

Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant’s Annual Report on Form 10-K, filed on March 13, 2023)

Exhibit 3.3 CURIS, INC. AMENDED AND RESTATED BY-LAWS (Amended and Restated as of March 7, 2023) TABLE OF CONTENTS Section 1. Certificate of Incorporation and By-Laws 1 1.1. Conflicts 1 1.2. References 1 Section 2. Offices 1 2.1. Registered Office 1 2.2. Other Offices 1 Section 3. Stockholders 1 3.1. Location of Meetings 1 3.2. Annual Meeting 1 3.3. Special Meeting in Place of Annual Meeting 1 3.4.

You’ve Exceeded the SEC’s Traffic Limit

EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2023 Curis, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2023 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 10.32 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Purchase and Sale Agreement Dated as of December 11, 2012 between Curis, Inc., as Seller, and Curis Royalty LLC, as Buyer Table of Contents Section Heading Pa

Curis Provides Fourth Quarter 2022 Business Update Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.m. ET

PRESS RELEASE Curis Provides Fourth Quarter 2022 Business Update Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Curis, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions

Amended and Restated By-Laws of Curis, Inc.

EX-3.1 2 curis-amendedandrestatedby.htm EX-3.1 Exhibit 3.1 CURIS, INC. AMENDED AND RESTATED BY-LAWS (Amended and Restated as of March 7, 2023) TABLE OF CONTENTS Section 1. Certificate of Incorporation and By-Laws 1 1.1. Conflicts 1 1.2. References 1 Section 2. Offices 1 2.1. Registered Office 1 2.2. Other Offices 1 Section 3. Stockholders 1 3.1. Location of Meetings 1 3.2. Annual Meeting 1 3.3. Sp

CRIS / Curis, Inc. / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

JOINT FILING AGREEMENT

EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Curis, Inc. dated as of February 14, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under

Power of Attorney

EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in -fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or any affiliate of either, all do

SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING CURIS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 231269200 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

Curis Provides Third Quarter 2022 Business Update Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended into

PRESS RELEASE Curis Provides Third Quarter 2022 Business Update Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended into 2025 Management to host conference call today at 4:30 p.

Employment Agreement, entered into on August 4, 2022, by and between Curis, Inc. and Diantha Duvall

EXHIBIT 10.1 EMPLOYMENT AGREEMENT - DUVALL THIS EMPLOYMENT AGREEMENT (the “Agreement”), made as of August 4, 2022, is entered into by and between Curis, Inc., a Delaware corporation (the “Company”), and Diantha Duvall (the “Employee”). WHEREAS, the Company desires to continue to employ the Employee, and the Employee desires to continue to be employed by the Company on the revised terms set forth i

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 9, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 21, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 12, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

As filed with the Securities and Exchange Commission on October 7, 2022

As filed with the Securities and Exchange Commission on October 7, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per sh

Kunkel, M.D., dated September 19, 2022

Exhibit 17.1 Lori A. Kunkel, MD [Address 1] [Address 2] [Phone] [email] 19 September, 2022 Jim Dentzer 128 Spring Street Building C-Suite 500 Lexington MA 02421 Dear Jim, This letter represents my official notice or resignation from my board position with Curis, Inc which is to be made final on the 30 day of September 2022. I regretfully announce this decision due to fundamental difference in beli

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 19, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number)

FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023

Exhibit 99.1 PRESS RELEASE FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., August 30, 2022 /PRNewswire/ ? Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics f

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 26, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 12, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023

Exhibit 99.1 PRESS RELEASE FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., August 18, 2022 /PRNewswire/ ? Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibruti

Exhibit 99.1 Curis Reports Second Quarter 2022 Financial Results and Business Update Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) Appointed Industry Veteran Diantha Duvall as Chief

Consulting Agreement, entered into on June 29, 2022, by and between Curis, Inc. and William E. Steinkrauss

Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement, effective as of August 5, 2022 (?Effective Date?), is by and between Curis, Inc., having a place of business at 128 Spring Street, Building C- Suite 500, Lexington, MA 02421("Curis"), and William E. Steinkrauss ("Consultant"). WHEREAS, Curis desires to have the benefit of Consultant's knowledge and experience, and Consultant desires to p

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2022 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (IRS

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2022 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (IRS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 5, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S

Curis Reports First Quarter 2022 Financial Results and Business Update

Exhibit 99.1 Curis Reports First Quarter 2022 Financial Results and Business Update Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer highlighted in a publication from Washington University in St. Louis Management to host conference call today at 4:30 p.m.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid

Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) Curis voluntarily paused enrollment in this study earlier

Exhibit 99.1 PRESS RELEASE Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) Curis voluntarily paused enrollment in this study earlier LEXINGTON, Mass., April 11, 2022 ? Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Adminis

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 11, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 1, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Exhibit 99.1 PRESS RELEASE Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948) LEXINGTON, Mass., April 4, 2022 ? Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Com

Power of Attorney

Exhibit 24.2 POWER OF ATTORNEY I, the undersigned director of Curis, Inc., hereby constitute and appoint James E. Dentzer and William E. Steinkrauss, and each of them singly, my true and lawful attorneys-in-fact with full power to any of them, and to each of them singly, to sign for me and in my name in the capacity indicated below any and all amendments (including post-effective amendments) to th

Terms and Conditions of Incentive Stock Option Agreement

Notice of Grant of Stock Options and Option Agreement Curis, Inc. ID: 04-3505116 128 Spring Street Lexington, MA 02421 %%FIRSTNAME%-% %%LASTNAME%-% Option Number: %%OPTIONNUMBER%-% %%ADDRESSLINE1%-% Plan: %%EQUITYPLAN%-% %%CITY%-%, %%STATE%-% %%ZIPCODE%-% ID: %%EMPLOYEEIDENTIFIER%-% Effective %%OPTIONDATE,'MM/DD/YYYY'%-% (?Grant Date?), you have been granted a(n) Incentive Stock Option to buy a sp

As filed with the Securities and Exchange Commission on February 24, 2022

Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 24, 2022 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number)

As filed with the Securities and Exchange Commission on February 24, 2022

Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No.

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 14 CURIS, INC. AMENDED AND RESTATED CODE OF BUSINESS CONDUCT AND ETHICS Adopted: December 12, 2017 This Code of Business Conduct and Ethics (the ?Code?) sets forth legal and ethical standards of conduct for directors, officers and employees of Curis, Inc. (the ?Company?). This Code is intended to deter wrongdoing and to promote the conduct of all Company business in accordance with high st

Calculation of Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 1 to Form S-3 (Form Type) Curis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou

You’ve Exceeded the SEC’s Traffic Limit

Notice of Grant of Stock Options and Option Agreement Curis, Inc. ID: 04-3505116 128 Spring Street Lexington, MA 02421 %%FIRSTNAME%-% %%LASTNAME%-% Option Number: %%OPTIONNUMBER%-% %%ADDRESSLINE1%-% Plan: %%EQUITYPLAN%-% %%CITY%-%, %%STATE%-% %%ZIPCODE%-% ID: %%EMPLOYEEIDENTIFIER%-% Effective %%OPTIONDATE,'MM/DD/YYYY'%-% (?Grant Date?), you have been granted a(n) Non-Qualified Stock Option to buy

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 10.38 FINAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT This First Amendment to Collaboration, License and Option Agreement (the ?Amendment?) is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specifie

Curis Reports Fourth Quarter and Year End 2021 Financial Results

Exhibit 99.1 Curis Reports Fourth Quarter and Year End 2021 Financial Results ? Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes ? ? Presented initial clinical data from Phase 1 study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors ? ? Adopt

You’ve Exceeded the SEC’s Traffic Limit

EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 10.37 FINAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION, LICENSE AND OPTION AGREEMENT This Collaboration, License and Option Agreement (the ?Agreement?) is entered into as of January 18, 2015 (t

DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Curis, Inc. (?us,? ?our,? ?we? or the ?Company?) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions

CRIS / Curis, Inc. / MAVERICK CAPITAL LTD - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

CRIS / Curis, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Curis, Inc. (Title of Class of Securities) Common Stock, Par Value $0.01 Per Share (C

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

JOINT FILING AGREEMENT

EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Curis, Inc.

Power of Attorney

EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in -fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or any affiliate of either, all documents

CRIS / Curis, Inc. / Sio Capital Management, LLC - AMENDMENT NO. 1 Passive Investment

CUSIP No. 231269200 Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

CRIS / Curis, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - CURIS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Curis, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which t

First Amendment to Lease Agreement, dated January 27, 2022, by and between Curis, Inc. and 99 Hayden, LLC, successor-in-interest to 128 Spring Street Lexington, LLC.

Exhibit 10.1 LEDGEMONT TECHNOLOGY CENTER Lexington, Massachusetts FIRST AMENDMENT TO LEASE Curis, Inc. First Amendment to Lease (?First Amendment?) dated as of January 27, 2022 between 99 Hayden LLC, a Delaware limited liability company, successor-in-interest to 128 Spring Street Lexington, LLC, a Delaware limited liability company (?Landlord?), and Curis, Inc., a Delaware corporation (?Tenant?).

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2022 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commi

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients wit

Exhibit 99.2 PRESS RELEASE Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors 40% CR/CRh rate (complete remission and complete remission with partial hematologic r

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2022 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (I

Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended

CA-4948 & CI-8993 Clinical Data Update January 2022 Exhibit 99.1 Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (?we,? ?us,? or the ?Company?) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ?expect(s),? ?believe(s),? ?will,? ?may,? ?anticipate(s),? ?focus(es)

Curis Appoints John A. Hohneker, M.D. to Board of Directors

Exhibit 99.1 PRESS RELEASE Curis Appoints John A. Hohneker, M.D. to Board of Directors LEXINGTON, Mass., December 6, 2021 /PRNewswire/ ? Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug develo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (

CRIS / Curis, Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CURIS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 9, 2021 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Curis Reports Third Quarter 2021 Financial Results and Business Update

Exhibit 99.1 Curis Reports Third Quarter 2021 Financial Results and Business Update Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Presented additional preclinical data for CA-4948 demonstrating potential in additional hematologic malignancies at AACR-NCI-EORTC Virtual Conference on

Restated Certificate of Incorporation of Curis, Inc., as amended

EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. CURIS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), hereby certifies as follows: The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of St

As filed with the Securities and Exchange Commission on October 15, 2021

As filed with the Securities and Exchange Commission on October 15, 2021 Registration No.

Restated Certificate of Incorporation of Curis, Inc., as amended.

Exhibit 4.1 RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. CURIS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), hereby certifies as follows: The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of St

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 3, 2021 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Curis Reports Second Quarter 2021 Financial Results

Exhibit 99.1 Curis Reports Second Quarter 2021 Financial Results ? Presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA) ? ? Clear anticancer activity observed in molecularly-enriched AML/MDS population with spliceosome or FLT3 mutat

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 11, 2021 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Exhibit 99.1 Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes ? Updated data show marrow blast reductions in 10 out of 12 evaluable patients with elevated blast counts at baseline ? ? 5 objective responses observed, including 1 complete response (CR), 1 complete rem

Certificate of Amendment of Restated Certificate of Incorporation of Curis, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CURIS, INC. Curis, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated C

CURIS, INC. FOURTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN

Exhibit 99.1 CURIS, INC. FOURTH AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this Fourth Amended and Restated 2010 Stock Incentive Plan (the ?Plan?) of Curis, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2021 Curis, Inc. (Exact name of registrant as specified in charter) Delaware 000-30347 04-3505116 (State or other jurisdiction of incorporation) (Commission File Number) (IRS

Curis Reports First Quarter 2021 Financial Results

Exhibit 99.1 Curis Reports First Quarter 2021 Financial Results ? Abstract with encouraging clinical data from Phase 1/2 study of CA-4948 in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) was released earlier today; additional clinical data to be presented in oral presentation at the European Hematology Association 2021 Virtual Congress (EHA) ? ? Phase 1/2 study in AML

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2021 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide

2021 Annual Meeting of Stockholders

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy S

- PRE 14A

PRE 14A 1 d88919dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the ap

CUSIP No. 231269200

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Curis, Inc. (Title of Class of Securities) Common Stock, Par Value $0.01 Per Share (CUS

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

Double asterisks denote omissions.

Exhibit 10.37 FINAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION, LICENSE AND OPTION AGREEMENT This Collaboration, License and Option Agreement (the ?Agreement?) is entered into as of January 18, 2015 (t

Form of Subordinated Note

Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Curis Reports Fourth Quarter and Year-End 2020 Financial Results

Exhibit 99.1 Curis Reports Fourth Quarter and Year-End 2020 Financial Results - Significantly expanded IRAK4 inhibitor CA-4948 development to include Phase 1 CA-4948 monotherapy study in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Phase 1 CA-4948/ibrutinib combination study in patients with relapsed or refractory (R/R) hematologic malignancies, Phase 2 LUCAS Investigator Spon

Sales Agreement by and among the Registrant, Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC

Exhibit 1.2 CURIS, INC. Common Stock ($0.01 par value per share) Sales Agreement March 16, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: Curis, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (?Cantor?) and JonesTrading Institu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 16, 2021 Curis, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30347 04-3505116 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT SUBSIDIARY NAME JURISDICTION OF ORGANIZATION DOING BUSINESS AS Curis Securities Corporation Massachusetts Curis Securities Corporation Curis Royalty LLC Delaware Curis Royalty LLC

Form of Subordinated Indenture

Exhibit 4.4 CURIS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicab

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specifie

Powers of Attorney (included in the signature pages to the Registrant’s initial Registration Statement on Form S-3 (No. 333-254362) filed on March 16, 2021)

Table of Contents As filed with the Securities and Exchange Commission on March 16, 2021 Registration No.

FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT

Exhibit 10.38 FINAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT This First Amendment to Collaboration, License and Option Agreement (the ?Amendment?) is

CURIS, INC. AMENDED AND RESTATED CODE OF BUSINESS CONDUCT AND ETHICS

Exhibit 14 CURIS, INC. AMENDED AND RESTATED CODE OF BUSINESS CONDUCT AND ETHICS Adopted: December 12, 2017 This Code of Business Conduct and Ethics (the ?Code?) sets forth legal and ethical standards of conduct for directors, officers and employees of Curis, Inc. (the ?Company?). This Code is intended to deter wrongdoing and to promote the conduct of all Company business in accordance with high st

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Curis, Inc. (?us,? ?our,? ?we? or the ?Company?) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions

Form of Senior Note

Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Form of Senior Indenture

Exhibit 4.3 CURIS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicable 314(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CURIS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) (CUSI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CURIS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

CUSIP No. 231269200 Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Curis, Inc. (Name of Issuer) Common Stock, Par Value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Curis, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) December 31,

Curis, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Curis, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 231269200 (CUSIP Number) January 21, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this